National Institute on Drug Abuse; Notice of Closed Meetings, 56966 [2022-20060]
Download as PDF
<![CDATA[
56966
Federal Register / Vol. 87, No. 179 / Friday, September 16, 2022 / Notices
for Public Comments’’ or by using the
search function.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Gisele Sarosy, MD,
Coordinating Center for Clinical Trials
(CCCT), National Cancer Institute, 9609
Medical Center Drive, 6W134,
Rockville, MD 20852 or call non-tollfree number 240–276–6172 or Email
your request, including your address to:
gisele.sarosy@nih.gov.
FOR FURTHER INFORMATION CONTACT:
This
proposed information collection was
previously published in the Federal
Register on June 29, 2022, page 38765
(Vol. 87, No. 124) and allowed 60 days
for public comment. One public
comment was received. The purpose of
this notice is to allow an additional 30
SUPPLEMENTARY INFORMATION:
Need and Use of Information
Collection: The Clinical Trials Reporting
Program (CTRP) is an electronic
resource that serves as a single,
definitive source of information about
all NCI-supported clinical research. This
resource allows the NCI to consolidate
reporting, aggregate data, and reduce
redundant submissions. Clinical
research administrators submit
information as designees of clinical
investigators who conduct NCIsupported clinical research. The
designees can electronically access the
CTRP website to complete the initial
trial registration. After registration, four
amendments and four study subject
accrual updates occur per trial annually.
days for public comment. The National
Cancer Institute (NCI), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: The Clinical
Trials Reporting Program (CTRP)
Database (NCI), 0925–0600, Expiration
Date 10/31/2022—EXTENSION,
National Cancer Institute (NCI),
National Institutes of Health (NIH).
OMB approval is requested for three
years. There are no costs to respondents
other than their time. The estimated
annualized burden hours are 18,000.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average time
per response
(in hours)
Total annual
burden hours
Type of respondents
Initial Registration .............................
Amendment .......................................
Update ...............................................
Accrual Updates ................................
Clinical Trials ....................................
3,000
1,500
1,500
3,000
1
4
4
4
1
1
1
15/60
3,000
6,000
6,000
3,000
Totals .........................................
...........................................................
9,000
27,000
........................
18,000
Dated: September 13, 2022.
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
[FR Doc. 2022–20083 Filed 9–15–22; 8:45 am]
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Animal Genomics Program.
Date: October 25, 2022.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827–4471,
ramadanir@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Single
Cell Opioid Responses in the Context of HIV
(SCORCH) Program Expansion: CNS Data
Generation for Chronic Opioid,
Methamphetamine, Cocaine and/or
Cannabinoid Exposures.
Date: November 22, 2022.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
Form name
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
16:43 Sep 15, 2022
Jkt 256001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: September 12, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–20060 Filed 9–15–22; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\16SEN1.SGM
16SEN1
]]>Agencies
[Federal Register Volume 87, Number 179 (Friday, September 16, 2022)]
[Notices]
[Page 56966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-20060]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Animal Genomics Program.
Date: October 25, 2022.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 827-4471,
[email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Single Cell Opioid Responses in the Context of HIV
(SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid,
Methamphetamine, Cocaine and/or Cannabinoid Exposures.
Date: November 22, 2022.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Research, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 12, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-20060 Filed 9-15-22; 8:45 am]
BILLING CODE 4140-01-P
